CEO David Happel was paid $3,239,994 in fiscal year 2025, ↑ up 257.6% from fiscal year 2024 (SEC filing 0001104659-26-046006 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,239,994 ↑ David Happel total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
SGMT's next annual pay disclosure, estimated April 12, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Happel | $630,000 | $0 | $546,360 | $1,749,751 | $294,525 | $0 | $19,358 | $3,239,994 |
| President and Chief Executive Officer | ||||||||
| Elizabeth Rozek | 483,333 | 0 | 235,137 | 591,668 | 170,000 | 0 | 16,564 | 1,496,702 |
| Chief Legal and Administrative Officer | ||||||||
| Eduardo Martins | 500,000 | 0 | 160,140 | 511,580 | 170,000 | 0 | 19,121 | 1,360,841 |
| Former Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Happel | $3,239,994 | $906,164 | $2,685,917 | ↑ +2,333,830 |
| Elizabeth Rozek | 1,496,702 | — | — | — |
| Eduardo Martins | 1,360,841 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Sagimet Biosciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SGMT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name SGMT as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Anne Phillips, M.D | Independent Director | $157,109 |
| Beth Seidenberg, M.D | Lead Independent Director | $316,278 |
| Elizabeth Grammer, Esq | Independent Director | $179,864 |
| George Kemble, Ph.D | Chair of the Board | $175,590 |
| Jennifer Jarrett | Independent Director | $157,303 |
| Merdad Parsey, M.D., Ph.D | Former director (through FY2025) | $21,863 |
| Paul Hoelscher | Independent Director | $184,864 |
| Timothy P. Walbert | Independent Director | $182,364 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Happel | RSU | 312,455 | — | $1,849,734 |
| David Happel | Option | 210,786 | 7.15 | — |
| Elizabeth Rozek | RSU | 34,000 | — | 201,280 |
| Elizabeth Rozek | RSU | 85,710 | — | 507,403 |
| Elizabeth Rozek | RSU | 9,855 | — | 58,342 |
| Elizabeth Rozek | Option | 13,089 | 7.61 | — |
| David Happel | RSU | 116,000 | — | 686,720 |
| Elizabeth Rozek | Option | 80,704 | 13.51 | — |
| Eduardo Martins | RSU | 44,785 | — | 265,127 |
| Eduardo Martins | RSU | 34,000 | — | 201,280 |
| David Happel | Option | 373,667 | 4.71 | — |
| Elizabeth Rozek | Option | 109,250 | 4.71 | — |
| Eduardo Martins | Option | 14,665 | 13.51 | — |
| Eduardo Martins | Option | 109,250 | 4.71 | — |
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Beth Seidenberg, M.DIndependent · Lead Independent Director · Compensation (Chair) | $66,331 | $129,864 | — | — | $120,083 | $316,278 |
| Paul HoelscherIndependent | 55,000 | 129,864 | — | — | 0 | 184,864 |
| Timothy P. WalbertIndependent | 52,500 | 129,864 | — | — | 0 | 182,364 |
| Elizabeth Grammer, EsqIndependent · Nominating/Governance (Chair) | 50,000 | 129,864 | — | — | 0 | 179,864 |
| George Kemble, Ph.DNot independent · Board Chair | 45,726 | 129,864 | — | — | 0 | 175,590 |
| Jennifer JarrettIndependent | 47,500 | 109,803 | — | — | 0 | 157,303 |
| Anne Phillips, M.DIndependent · Compensation · Nominating/Governance | 47,306 | 109,803 | — | — | 0 | 157,109 |
| Merdad Parsey, M.D., Ph.DIndependent · Departed during FY | 21,863 | 0 | — | — | 0 | 21,863 |
| David HappelEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $386,226 |
| Equity awards (grant-date value) | $868,926 |
| All other compensation | $120,083 |
| Total cost of the board | $1,375,235 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Sagimet Biosciences | 2025 | David Happel | $630,000 | $546,360 | $1,749,751 | $294,525 | $3,239,994 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, David Happel | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Executive Compensation”. As printed: 3,239,994. Filing ↗machine: r1 · c41 · span 473817–473826 |
| 2 | Section 01, Elizabeth Rozek | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Executive Compensation”. As printed: 1,496,702. Filing ↗machine: r3 · c41 · span 483283–483292 |
| 3 | Section 01, Eduardo Martins | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Executive Compensation”. As printed: 1,360,841. Filing ↗machine: r5 · c41 · span 492646–492655 |
| 4 | Section 08, Beth Seidenberg, M.D | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 316,278. Filing ↗machine: span 387506–387513 |
| 5 | Section 08, Paul Hoelscher | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 184,864. Filing ↗machine: span 384437–384444 |
| 6 | Section 08, Timothy P. Walbert | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 182,364. Filing ↗machine: span 395829–395836 |
| 7 | Section 08, Elizabeth Grammer, Esq | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 179,864. Filing ↗machine: span 381812–381819 |
| 8 | Section 08, George Kemble, Ph.D | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 175,590. Filing ↗machine: span 398897–398905 |
| 9 | Section 08, Jennifer Jarrett | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 157,303. Filing ↗machine: span 393200–393207 |
| 10 | Section 08, Anne Phillips, M.D | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 157,109. Filing ↗machine: span 390136–390143 |
| 11 | Section 08, Merdad Parsey, M.D., Ph.D | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 21,863. Filing ↗machine: span 400027–400033 |
| 12 | Section 08, David Happel | DEF 14A | 2026-04-21 | 0001104659-26-046006 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | — | Cash 386,226 + equity 868,926 + all other 120,083 = 1,375,235, summed across the director compensation table rows.machine: formula: Σ = 1,375,235 |
| 15 | Sagimet Biosciences (subject), Section 10b CEO total | DEF 14A | 2026-04-21 | 0001104659-26-046006 | CEO total compensation as printed in Sagimet Biosciences's own proxy. As printed: 3,239,994. Filing ↗machine: r1 · c41 · span 473817–473826 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.